An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

PHASE4CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

February 19, 2013

Primary Completion Date

February 17, 2020

Study Completion Date

February 17, 2020

Conditions
Neoplasms
Interventions
DRUG

Vemurafenib

Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).

Trial Locations (83)

324

Mansoura University Hospital, Dakahlia

1000

Institut Jules Bordet, Brussels

1023

Auckland City Hospital, Auckland

1083

Semmelweis Egyetem, Budapest

1122

Orszagos Onkologiai Intezet, Budapest

2006

Bank of Cyprus Oncology Center, Nicosia

2193

Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg

4012

Debreceni Egyetem Klinikai Központ; Bőrgyógyászati Klinika, Debrecen

6045

Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth

7570

Cape Town Oncology Trials, Cape Town

7624

Pecsi Tudomanyegyetem, Pécs

8011

Christchurch Clinical Studies Trust, Christchurch

10000

Clinical Hospital Center Sestre Milosrdnice, Zagreb

Clinical Hospital Centre Zagreb, Zagreb

10016

New York University Medical Center PRIME, New York

10065

Evelyn H. Lauder Center, New York

11000

Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade

11070

Clinical Center Bezanijska Kosa, Belgrade

11796

National Cancer Institute, Cairo

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

19104

University of Pennsylvania Health System, Philadelphia

21131

Medical Research Institute, Alexandria

28034

Hospital Universitario Ramón y Cajal, Madrid

28040

Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

29010

Hospital Regional Universitario de Malaga; Oncologia, Málaga

30202

Hospital General Universitario Santa Lucia, Cartagena (Murcia)

37007

Hospital Universitario de Salamanca, Salamanca

39008

Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander

41009

Hospital Universitario Virgen Macarena, Seville

41404

Kyungpook National University Chilgok Hospital, Daegu

46009

Instituto Valenciano Oncologia; Oncologia Medica, Valencia

46014

Hospital General Universitario de Valencia, Valencia

51108

Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke, Mainz

56100

Azienda Ospedaliero Universitaria Pisana, Pisa

60637

University of Chicago Medical Center; Medicine, Section of Pulmonary, Chicago

69120

Universitätsklinikum Heidelberg, Heidelberg

69373

Centre Léon Bérard, Lyon

71000

University Clinic Centre Sarajevo, Sarajevo

72758

Highlands Oncology Group, Rogers

75246

Mary Crowley Medical Research Center; Oncology, Dallas

77598

M D Anderson Physician Network, Webster

78000

University Clinical Center of the Republic of Srpska, Banja Luka

90024

UCLA Department of Medicine, Los Angeles

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

94805

Institut Gustave Roussy, Villejuif

97080

Universitätsklinikum Wurzburg, Würzburg

98195

University of Washington Seattle Cancer Care Alliance, Seattle

115478

"FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin; Chemotherapy Departement", Moskva

143423

Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow

197022

"St. Petersburg SHI City Clinical Oncology Dispensary", Saint Petersburg

223040

N.N. Alexandrov National Cancer Centre of Belarus, Minsk District

280146

Hospital Universitario La Paz, Madrid

350040

"SBIH Clinical Oncological Dispensary # 1; Chemotherapy department #1 and #2", Krasnodar

400058

Medisprof SRL, Cluj-Napoca

420029

Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan'

450054

SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa

3109600

Rambam Health Care Campus, Haifa

5266202

Chaim Sheba Medical Center; Allergy and Clinical Immunology Unit, Ramat Gan

6423906

Tel-Aviv Sourasky Medical Center, Tel Aviv

9112001

Hadassah University Hospital - Ein Kerem, Jerusalem

02114

Massachusetts General Hospital Cancer Center, Boston

Unknown

Hospital das Clinicas - UFRGS, Porto Alegre

Gharbia Cancer Society, Tanta

Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milan

H3T 1E2

McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal

711 10

University General Hospital of Heraklion, Crete

H-1077

Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest

6229 HX

Maastricht University Medical Center, Maastricht

1099-023

IPO de Lisboa; Servico de Oncologia Medica, Lisbon

4200-072

IPO do Porto; Servico de Oncologia Medica, Porto

(0)6351

Samsung Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

07010

Hospital Universitario Son Espases, Palma de Mallorca

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

OX3 7LJ

Churchill Hospital, Oxford

SM2 5PT

Royal Marsden Hospital, Surrey

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01739764 - An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | Biotech Hunter | Biotech Hunter